These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30854898)

  • 1. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
    Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
    Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in renal cell carcinoma.
    Ross K; Jones RJ
    Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitors in hematological malignancies.
    Ok CY; Young KH
    J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
    Kim YJ; Lee JS; Lee J; Lee SC; Kim TI; Byeon SH; Lee CS
    Cancer Immunol Immunother; 2020 Dec; 69(12):2441-2452. PubMed ID: 32556494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
    Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
    Front Immunol; 2018; 9():2204. PubMed ID: 30319648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.
    Su X; Li J; Xu X; Ye Y; Wang C; Pang G; Liu W; Liu A; Zhao C; Hao X
    J Transl Med; 2024 Aug; 22(1):751. PubMed ID: 39123227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
    Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
    Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
    Myint ZW; Goel G
    J Hematol Oncol; 2017 Apr; 10(1):86. PubMed ID: 28434400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
    Assal A; Kaner J; Pendurti G; Zang X
    Immunotherapy; 2015; 7(11):1169-86. PubMed ID: 26567614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
    Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
    ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Resistance to Immune Checkpoint Blockade.
    Liu D; Jenkins RW; Sullivan RJ
    Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.
    Haeryfar SMM; Schell TD
    Cancer Immunol Immunother; 2018 Nov; 67(11):1669-1672. PubMed ID: 30132082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
    Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
    Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on the clinical development of immunotherapy in prostate cancer.
    Cordes LM; Gulley JL; Madan RA
    Asian J Androl; 2018; 20(3):253-259. PubMed ID: 29582792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
    Haibe Y; El Husseini Z; El Sayed R; Shamseddine A
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
    J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.